Rock Springs Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Rock Springs Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-257,253	Closed	-$8.61M	–	114
2026 Q1	$8.61M	Buy	257,253 +10,200	+4%	+$400K	0.51%	51
2025 Q4	$11.4M	Buy	247,053 +92,525	+60%	+$5.07M	0.59%	50
2025 Q3	$10.4M	Hold	154,528	–	–	0.61%	51
2025 Q2	$12.9M	Buy	154,528 +30,433	+25%	+$2.28M	0.81%	43
2025 Q1	$8.87M	Hold	124,095	–	–	0.51%	55
2024 Q4	$5.58M	Buy	+124,095	New	+$6.43M	0.21%	74

Rock Springs Capital Management's SLNO Position: Q2 2026 in Review

Rock Springs Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 257,253 shares — an estimated $8.61M sold.

Rock Springs Capital Management first reported a position in SLNO in Q4 2024 and held it in 6 quarters. The position peaked at $12.9M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Rock Springs Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Rock Springs Capital Management sold 257,253 Soleno Therapeutics shares in Q2 2026, an estimated $8.61M.
Rock Springs Capital Management first reported a position in Soleno Therapeutics in Q4 2024 and held it in 6 quarters.
Rock Springs Capital Management's Soleno Therapeutics position peaked at $12.9M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.